Table 1.
Procedure | Screening | Intervention | Follow-up | Frequency | Duration (mins) | Performed by: |
---|---|---|---|---|---|---|
Informed Consent | X | 1x | 45 | Study team | ||
Demographics | X | 1x | 5 | Study team | ||
Medical History | X | 1x | 15 | Study team | ||
Physical Assessment | X | 1x | 5 | Study team | ||
Confirmation of Eligibility | X | 1x | 15 | Study team | ||
tDCS | X | 1x daily for max. 14 days | 30 | Study team (or trained carer) | ||
Seizure diary | X | X | 3x daily for max. 15 days | varies | Patient/carer/legal guardian | |
Video monitoring of seizure area (if consented) | X | X |
1x daily for max. 15 days |
5 | Patient/carer/legal guardian | |
Accelerometery recordings | X | X | 2x | Continuous |
Patient/legal guardian/ or study team |
|
Adverse Event Reporting | X | X | X | Max. 15 days | 20 | Study team |
End-of-study EEG | X | 1x | 30 | Study team |
Note Administration of tDCS will end with resolution of the focal epileptic event (i.e. seizure freedom), or after 14 days, whichever happens earlier